A company that makes things people put directly onto their eyeballs has an unusually literal relationship with the word precision. Bausch + Lomb has just demonstrated it in the boardroom instead. Chief executive Brent Saunders is leaving by mutual agreement, chairman Thomas Appio steps in as interim chief, and in the same breath both Bausch entities raised their 2026 EBITDA guidance. The departure and the upgrade arrived together, which is not an accident.
Guidance moving up on the day a chief executive moves out is the detail that reorganises the whole story. The usual pattern when a leader leaves abruptly is a simultaneous softening of expectations, because the easiest moment to reset the numbers is the moment nobody is left to own them. Doing the opposite is a deliberate statement about what kind of transition this is. The message to holders is that the operating performance is not in question, the trajectory is intact, and whatever drove the change sat above the operating line.
Context matters here more than it usually does. Bausch + Lomb has spent years inside a structure that nobody has been able to settle. It was carved partially out of its parent, remained majority-held by it, and has existed since then as a company whose strategic future belonged to a question rather than a plan. A sale process that collapsed in 2025 is the clearest evidence of that. Running an operating business while its ownership architecture is an open item is a particular form of difficulty, because every major capital decision gets asked twice, once on its merits and once on what it does to a separation that may or may not happen.
The coffee parallel is in the cup, not the boardroom. A properly pulled espresso is defined by extraction time, and the skill is knowing when to stop. Pull too short and it is sharp and incomplete. Pull too long and the bitter compounds arrive and spoil everything that came before. A separation process has the same window. Drag it across years and the business starts paying for the uncertainty in deferred investment, cautious hiring and management attention spent on structure instead of product.
The insight is about what an interim appointment from the chairman’s seat actually does. It is not a gap-filling exercise. Putting the chairman in as chief executive collapses the distance between the body deciding the company’s structural future and the person running its operations, which is the fastest available route to resolving a question that has been open too long. It is also, candidly, the configuration a board reaches for when it wants decisions made rather than recommendations prepared.
Meanwhile the underlying business is doing what the guidance upgrade says it is doing. Contact lenses, lens care, surgical equipment and ophthalmic pharmaceuticals form a portfolio with genuine durability: ageing populations, a global rise in myopia, a product that is consumed and replaced rather than bought once, and surgical franchises where hospitals switch suppliers slowly. That is a good business regardless of whose name sits on the chief executive letterhead, and raising the outlook while the letterhead is being reprinted is the board saying so with numbers rather than adjectives.
Two Bausch entities, one unresolved structure, a chief executive out and a chairman in. The one thing that went up on the day everything else moved was the forecast, and that is the sentence to keep.
Source: Reuters, “Bausch + Lomb CEO Saunders steps down, chairman Appio appointed interim chief”
